Category: News
PROUD Project Presented at the 15th International Conference of the Center for Applied Neuroscience
No Comments
| News
We are pleased to announce that our Ph.D. student Morfeas Koumas presented our “PROUD” project at the 15th International Conference of the Center of Applied Neuroscience, held at the University of Cyprus. Morfeas’s poster presentation showcased our ongoing randomized, double-blind, placebo-controlled clinical trial investigating the efficacy of ketamine in treating negative affect and preventing relapse […]
Dr. Zanos was invited to give a talk at the Foundation for Research and Technology in Crete about our ongoing studies on ketamine and opioid use disorders
Dr. Panos Zanos was recently invited to present at the Foundation for Research and Technology (FORTH) in Crete, where he shared insights into the Zanos Lab’s pioneering work on ketamine and opioid use disorders. His presentation focused on the PROUD study, a groundbreaking clinical trial investigating the therapeutic potential of ketamine in individuals with opioid […]
Morfeas Koumas awarded a FENS/IBRO-PERC Fellowship for advanced training in Barcelona
We are delighted to announce that our first-year Ph.D. student, Morfeas Koumas (BSc, MSc), has been awarded the FENS/IBRO-PERC Fellowship to conduct a six-week research exchange at the University of Barcelona. Morfeas will train under the mentorship of Dr. Jordi Bonaventura, an expert in addiction neuroscience and behavioral pharmacology. This fellowship represents a crucial step […]
Dr. Andria Michael presents research on ketamine-based therapies for opioid relapse prevention
Dr. Andria Michael, a postdoctoral researcher in the Zanos Lab, recently represented our laboratory at the 13th International Multithematic Scientific Bio-Medical Congress in Cyprus, at the European University Cyprus School of Medicine. Her presentation highlighted groundbreaking work on novel pharmacotherapies for preventing relapse to opioid use disorders during abstinence. The research focuses on ketamine, a […]
New pre-print: VirTarget framework reveals how Multiple Sclerosis immunotherapies engage with Epstein-Barr Virus-driven disease mechanisms
The AI & Systems Bioinformatics Unit of the Translational Neuropharmacology Lab has released a new preprint introducing VirTarget, the first virus-informed pharmacogenomics framework designed to systematically evaluate how multiple sclerosis (MS) immunotherapies interact with Epstein-Barr virus (EBV)-driven pathogenesis. While EBV is increasingly recognized as a central driver of MS, current immunotherapies are prescribed without considering […]
New preprint: VirTrack framework reveals stage-specific EBV pathogenesis in Multiple Sclerosis
We’re excited to share our latest preprint, “VirTrack: A Framework for Inferring Viral Influence on Disease-Associated Transcriptomes — Clinical Type-Specific Epstein–Barr Virus Pathogenesis in Multiple Sclerosis,” now available on bioRxiv. This work, led by Dr. Anna Onisiforou, Head of our AI & Systems Bioinformatics Unit, represents a major advance in understanding how Epstein–Barr virus (EBV) […]
Translational Neuropharmacology Lab presents on novel therapies for brain disorders
Dr. Panos Zanos recently delivered a presentation on novel pharmacological therapies for brain diseases at the Ierokipio University in Paphos, Cyprus. The Ierokipio University is a lifelong learning initiative that brings scientific knowledge to the general public, fostering dialogue between researchers and community members on important health and medical topics. The presentation provided an overview […]
Dr. Zanos was invited and presented on antidepressant mechanisms of action of ketamine and other rapid-acting antidepressants at the 6th German-Cypriot Psychotherapy Conference
Dr. Panos Zanos delivered an invited presentation at the 6th German-Cypriot Conference Psychotherapy Dialogues, titled “Neurobiology of Depression: Traditional & Rapid-acting Pharmacotherapies.” The presentation addressed a critical challenge in psychiatry: conventional antidepressants require three to four weeks to produce therapeutic effects, with approximately thirty percent of patients failing to respond. Dr. Zanos explored the neurobiological […]
Featured in Nature Mental Health: Advancing ketamine research and brain pathology treatments
We are happy to share that Dr. Zanos, the Director of the Translational Neuropharmacology Lab, was recently featured in a Q&A article published by Nature Mental Health. The discussion explores our laboratory’s pioneering work on ketamine and its metabolites as novel treatments for brain pathologies, with particular emphasis on depression and substance use disorders. The […]
Researchers from the Zanos lab attend the European Researchers’ Night 2025
We are pleased to share that the Translational Neuropharmacology Lab participated in the European Researchers’ Night (ERN) 2025, held on September 26, 2025, at the Cyprus State Fair in Nicosia. This annual event, organized by the Research and Innovation Foundation, brings research and innovation closer to the public through interactive demonstrations and activities. Our team […]